Evento

Investigating anti-tumor effects of human innate T lymphocytes in vivo

Il 06/09/2019 ore 12.00 - 13.00

Sala Conferenze CNR, Area della Ricerca Na1, via Pietro Castellino 111, 80131 Napoli

Jenny E. Gumperz (University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA) will present a Seminar on the anti-tumor effects of human innate T lymphocytes in vivo.

Cellular immunotherapy using chimeric-antigen-receptor (CAR) T cells is rapidly revolutionizing the treatment of many different types of cancer. However, the underlying biology of T cell restriction by highly polymorphic HLA molecules and the resulting need for self-tolerance remains a central limitation to this approach. In contrast, innate T lymphocytes – including invariant natural killer T (iNKT) and Vγ9Vδ2 T cells – are restricted by conserved non-classical antigen presenting molecules, and have shown intrinsic anti-tumor functions.
As a pre-clinical tool to investigate the anti-tumor effects of human innate T cells in vivo, it has developed a humanized mouse model in which Epstein-Barr virus (EBV) is used to drive the de novo formation of human B lymphomas from human umbilical cord blood within immunodeficient NSG mice. Importantly, in this system the B-lymphomas form in the presence of naive autologous T lymphocytes that respond to the cancer but that are ultimately prevented from effectively clearing it by inhibitory pathways.

Thus, this model allows us to evaluate the impact of using allogeneic human innate T lymphocytes as a cellular immunotherapy.  Jenny E. Gumperz will discuss about recent studies on the contrasting immunotherapeutic features of Vγ9Vδ2 T cells and iNKT cells in this model system.

Organizzato da:
CNR - Istituto di Biochimica e Biologia Cellulare

Referente organizzativo:
Stefania Mariggiò
CNR - Istituto di Biochimica e Biologia Cellulare
via Pietro Castellino 111, 80131 Napoli
s.mariggio@ibp.cnr.it
081 6132545

Modalità di accesso: ingresso libero

Vedi anche: